Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Mereo BioPharma Group plc
MREO | US
0.33
USD0.01
2.81%
MREO | US
About Mereo BioPharma Group plc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
14/04/2026
Close
0.33
Open
0.32
High
0.34
Low
0.32
Mereo BioPharma Group plc a biopharmaceutical company develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate etigilimab (OMP-313M32) an antibody T-cell immunoreceptor with Ig and ITIM domains which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83) which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197) a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649) an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition it develops rare disease product candidates including Setrusumab (BPS-804) a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966) an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate etigilimab; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London the United Kingdom.
View LessMREO | US
Risk
54.2
Sharpe
-0.66
Luna's Score
45/100
Recommendation
Sell
Luna says (MREO | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
43.7%1 month
54.2%3 months
80.4%6 months
165.7%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
9.04
Debt to equity
0.08
Debt to assets
0.06
Ent. to EBITDA
-1.21
Ent. to rev.
629.53
PEG
-
Other Fundamentals
EBITDA
-37.31M
MarketCap
50.62M
MarketCap(USD)
50.62M
Div. yield
-
Op. margin
-3.79K
Erngs. growth
-
Rev. growth
-
Ret. on equity
-48.47
Short ratio
6.19
Short perc.
3.76
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.05
Range1M
0.09
Range3M
0.47
Volumes: Market Activity
Rel. volume
0.50
Price X volume
229.62K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -1.21 | - | Cheaper |
| Ent. to Revenue | 629.53 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 9.04 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 80.38 | - | Par |
| Debt to Equity | 0.08 | -1.23 | Expensive |
| Debt to Assets | 0.06 | 0.25 | Cheaper |
| Market Cap | 50.62M | - | Emerging |
